Control of cell cycle gene expression in bone development and during c- Fos-induced osteosarcoma formation

Developmental Genetics

Volumn 22, Issue 4, 1998, Pages 386-397

  Sunters, Andrew ^a   McCluskey, Jane ^a   Grigoriadis, Agamemnon E ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

c Fos; Cell cycle; Cyclin D; Cyclin E; Osteosarcoma; p27; Transgenic mice

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; PROTEIN C FOS; PROTEIN P27;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLAST TRANSFORMATION; BONE DEVELOPMENT; CARTILAGE CELL; CELL CYCLE; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; NEWBORN; NONHUMAN; ONCOGENE C FOS; OSTEOBLAST; OSTEOCLAST; OSTEOSARCOMA; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; BONE DEVELOPMENT; BONE NEOPLASMS; CELL CYCLE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-FOS;

ANIMALIA; MUS MUSCULUS;

EID: 0031831304     PISSN: 0192253X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6408(1998)22:4<386::AID-DVG8>3.0.CO;2-2     Document Type: Article

References (48)

1. Adelaide J, Monges G, Derderian C, Seitz JF, Birnbaum D (1995): Esophageal cancer and amplification of the human cyclin D gene CCND1/Prad1. Br J Cancer 71:64-68.
2. Angel P, Karin M (1991): The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1072: 129-157.
3. Balsabore A, Jolicoeur P (1995): Fos proteins can act as negative regulators of cell growth independently of the Fos transforming pathway. Oncogene 11:455-465.
4. Brüsselbach S, Möhle-Steinlein U, Wang ZQ, Schreiber M, Lucibello FC, Müller R, Wagner EF (1995): Cell proliferation and cell cycle progression are not impaired in fibroblasts and ES cells lacking c-Fos. Oncogene 10:79-86.
5. De Togni P, Niman H, Raymond V, Sawchenko P, Verma IM (1988): Detection of fos protein during osteogenesis by monoclonal antibodies. Mol Cell Biol 8:2251-2256.
6. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend SH (1990): p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10:5772-5781.
7. Dony C, Gruss P (1987): Proto-oncogene c-fos expression in growth regions of fetal bone and mesodermal web tissue. Nature 328:711-714.
8. Elledge SJ, Winston J, Harper JW (1996): A question of balance: The role of cyclin kinase inhibitors in development and tumorigenesis. Trends Cell Biol 6:38.8-392.
9. Fantl V, Stam G, Andrews A, Rosewell I, Dickson C (1995): Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 9:2364-2372.
10. Galaktionov K, Chen XC, Beach D (1996): Cdc25 cell cycle phosphatase as a target of c-Myc. Nature 382:511-517.
11. Gao CY, Zelenka PS (1997): Cyclins, cyclin dependent kinases and differentiation. BioEssays 19:307-315.
12. Grigoriadis AE, Schellander K, Wang ZQ, Wagner EF (1993): Osteoblasts are target cells for transformation in c-Fos transgenic mice. J Cell Biol 122:685-701.
13. Grigoriadis AB, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleish HA, Wagner EF (1994): c-Fos: A key regulator of osteoclast and macrophage lineage determination and bone remodeling. Science 266:443-448.
14. Grigoriadis AE, Wang ZQ, Wagner EF (1995): Fos and bone cell development: Lessons from a nuclear oncogene. Trends Genet 11:436-441.
15. Haas K, Johannes C, Geisen C, Schmidt T, Karsunky H, Blass-Kampmann S, Obe G, Möröy T (1997b): Malignant transformation by cyclin E and Ha-Ras correlates with lower sensitivity towards induction of cell death but requires functional Myc and CDK4. Oncogene 15:2615-2623.
16. Haas K, Staller P, Geisen C, Bartek J, Eilers M, Möröy T (1997a): Mutual requirement of CDK4 and Myc in malignant transformation: Evidence for cyclin D1/CDK4 and p16 (INK4A) as upstream regulators of Myc. Oncogene 15:179-192.
17. Hall M, Peters G (1996): Genetic alterations of cyclins, cyclin dependent kinases and Cdk inhibitors in human cancer. Adv Cancer Res 68:67-108.
18. Harper JW, Elledge SJ (1996): Cdk inhibitors in development and cancer. Curr Opin Genet Dev 6:56-64.
19. Hartwell HH, Kastan MB (1994): Cell cycle control and cancer. Science 266:1821-1828.
20. Herber B, Truss M, Beato M, Müller R (1994): Inducible regulatory elements in the human cyclin D1 promoter. Oncogene 9:1295-1304.
21. Hoyland J, Sharpe PT (1994): Up-regulation of c-Fos protooncogene expression in Pagetic osteoclasts. J Bone Miner Res 9:1191-1194.
22. Hunter T, Pines J (1994): Cyclins and cancer. 2. Cyclin D and Cdk inhibitors come of age. Cell 79:573-582.
23. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ (1997): Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19(ARF). Cell 91:649-659.
24. Kobayashi K, Phuchareon J, Inada K, Tomita Y, Koizumi T, Hatano M, Miyatake S, Tokuhisa T (1997): Overexpression of c-fos inhibits down regulation of a cyclin dependent kinase 2 inhibitor p27(Kip1) in splenic B cells activated by surface Ig cross linking. J Immunol 158:2050-2056.
25. Kovary K, Bravo R (1991): The Jun and Fos protein families are both required for cell cycle progression in fibroblasts. Mol Cell Biol 11:4466-4472.
26. La Thangue NB (1994): DRTF1/E2F - an expanding family of heterodimeric transcription factors implicated in cell cycle control. Trends Biochem Sci 19:108-114.
27. Lang Z, Feingold JM (1996): An autonomously replicating eukaryotic expression vector with a tetracycline-responsive promoter. Gene 168:169-171.
28. Lukas J, Bartkova J, Welcker M, Petersen OW, Peters G, Strauss M, Bartek J (1995): Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene 10:2125-2134.
29. Maelandsmo GM, Berner JM, Florenes VA, Forus A, Hovig E, Fodstad O, Myklebost O (1995): Homozygous deletion frequency and expression levels of CDKN2 gene in human sarcomas: Relationship to amplification and messenger RNA levels of Cdk4 and CCND1. Br J Cancer 72:393-398.
30. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ (1987): Rearrangement of the P53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84:7716-7719.
31. Miao CG, Curran T (1994): Cell transformation by c-Fos requires an extended period of expression and is independent of the cell cycle. Mol Cell Biol 14:4295-4310.
32. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP (1996): Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 86:136-142.
33. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989): Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-708.
34. Onishi T, Hruska K (1997): Expression of p27(Kip1) in osteoblast like cells during differentiation with parathyroid hormone. Endocrinology 138:1995-2004.
35. Perez-Roger I, Solomon DLC, Sewing A, Land H (1997): Myc activation of cyclin E Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene 14:2373-2381.
36. Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, Picci P, Levine AS, Carbone M (1996): Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 63:37-50.
37. Sherr CJ, Roberts JM (1995): Inhibitors of mammalian G(1) cyclin dependent kinases. Genes Dev 9:1149-1163.
38. Smith E, Frenkel B, MacLachan TK, Giordano A, Stein JL, Lian JB, Stein GS (1997): Post-proliferative cyclin E-associated kinase activity in differentiated osteoblasts: Inhibition by proliferating osteoblasts and osteosarcoma cells. J Cell Biochem 66:141-152.
39. Smith E, Frenkel B, Schlegel R, Giordano A, Lian JB, Stein JL, Stein GS (1995): Expression of cell cycle regulatory factors in differentiating osteoblasts postproliferative up-regulation of cyclin B and cyclin E. Cancer Res 55:5019-5024.
40. Vlach J, Henneck S, Alevizopoulos K, Conti D, Amati B (1996): Growth arrest by the cyclin dependent kinase inhibitor p27(Kip1) is abrogated by c Myc. EMBO J 15:6595-6604.
41. Wang HM, Rodgers WH, Chmell MJ, Svitek C, Schwartz HS (1995a): Osteosarcoma oncogene expression detected by in situ hybridization. J Orthop Res 13:671-678.
42. Wang ZQ, Grigoriadis AE, Möhle-Steinlein U, Wagner EF (1991): A novel target cell for c-fos-induced oncogenesis: Development of chondrogenic tumours in embryonic stem cell chimeras. EMBO J 10:2437-2450.
43. Wang ZQ, Liang J, Schellander K, Wagner EF, Grigoriadis AE (1995b): c-Fos-induced osteosarcoma formation in transgenic mice: Cooperativity with c-Jun and the role of endogenous c-Fos. Cancer Res 55:6244-6251.
44. Wang ZQ, Ovitt C, Grigoriadis AE, Möhle-Steinlein U, Rüther U, Wagner EF (1992): Bone and hematopoietic defects in mice lacking c-Fos. Nature 360:741-745.
45. Weinberg RA (1995): The retinoblastoma protein and cell cycle control. Cell 81:323-330.
46. Wu JX, Carpenter PM, Gresens C, Keh R, Niman H, Morris JWS, Mercola D (1990): The proto-oncogene c-Fos is overexpressed in the majority of human osteosarcomas. Oncogene 5:989-1000.
47. Zhang PM, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ (1997): Altered cell differentiation and proliferation in mice lacking p57(KIP2) indicates a role in Beckwith-Wiedemann syndrome. Nature 387:151-158.
48. Zindy F, Quelle DE, Roussel MF, Sherr CJ (1997): Expression of the p16(INK4a) tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15:203-211.